About the company

Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden. It offers Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company has a collaboration with Icahn School of Medicine to test biomarker guiding platin-immunotherapy in lung cancer. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.